Orphan Drugs Market

Orphan Drugs Market (Disease Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, and Infectious diseases; Product Type - Biologic and Non-biologic; Distribution Channel - Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

Global Orphan Drugs Market: Overview 

Orphan drug products are medicines for the therapy of life-threating or extremely severe illnesses or disorders which are uncommon for diagnosis, prevention or therapy. The pharmaceutical industry is little interested in the development and marketing of products designed for a tiny amount of patients under ordinary market circumstances. These medicines are called orphans. In 1983, the Orphan Drug Act was enacted to encourage drug companies to create rare disease therapy. The FDA Office for the Development of Orphan Products determines whether a drug is an orphan. 

The incredibly high costs of placing a medicinal product on the market in drug companies would not be recovered from anticipated product revenues. This also leads to a small market potential for fresh drug use and an economic loss for the drug companies sector. 

orphan drugs market

The worldwide orphan medicinal products market is expected to swell during the forecast period to give increasing significance to research and development operations. Over the forecast period 2017 to 2025 the international market for orphan drugs is expected to improve by 12.10 percent at CAGR. By the end of 2025, the worldwide market for orphan drugs should reach a net estimate of 318,5 billion US dollars. 

The global orphan drugs market is segmented by the disease type, by indicator, and by technology for study. Further, the market is considered in terms of different geographical regions in the report. 

Rising Prevalence of Rare Diseases to Strengthen Orphan Drugs Market 

Recurring, chronic and rare illnesses and the elevated demand for significant amounts of orphan drug production are currently forecast to affect around 300 million people worldwide. Rare disease medicines, such as Yellow Fever, von Willebrand Disease, Waardenburg Syndrome, Diabetes Macular Edema, Abetalypoproteinemia, ASD, Yellow Nail Syndrome or Von Hippel Lindau Syndrome and others, are increasing in demand for medicinal products that help increase the market. In addition, FDA free exemptions, public R&D grants, favourable reimbursement policies and premium pricing for business development. 

In 2019, it is likely that the U.S. will see around 1,762,450 new cancer cases, according to the National Center for Health Statistics. The demand for orphan medicines is likely to rise in the coming years as these figures are motivated. As a result, there have been a total of 4,171 drugs in the US as orphan drugs. Such Government initiatives encourage drug manufacturers to invest more in the said industry. 

Although the market for orphan medicines is developing at a decent rate, certain variables can impede its development. The elevated price of orphan medicines, inadequate data on rare illnesses and the absence of competent health experts are factors that reduce development in the worldwide market for orphan medicines. Furthermore, increasing competition from generic sectors can seriously threaten market growth. 

Global Orphan Drugs Market: Regional Outlook 

The global orphan drugs market is segmented for study into North America, Europe, and Rest of the World. Among these, North America is expected to register for high growth in the global market. 

There are several factors contributing to the development of the industry, including promoting laws that enable rapid approval of such drugs, drug status exclusivity for such drugs and a solid medical infrastructure. 

Global Orphan Drugs Market: Companies Mentioned 

Key vendors profiled in our report on the global orphan drugs market include Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Daiichi Sankyo Company Limited, Novo Nordisk A/S, Bayer AG, AstraZeneca plc., and Amgen Inc., among several others.

Orphan Drugs Market will Gain Significant Revenues from Growing Prevalence of Rare Diseases

Orphan drug items are medications for the treatment of life-threating or amazingly extreme ailments or problems which are phenomenal for conclusion, counteraction or treatment. The drug business is minimal keen on the turn of events and showcasing of items intended for a small measure of patients under conventional market conditions. These medications are called orphan drugs. The staggeringly significant expenses of setting a restorative item available in drug organizations would not be recuperated from expected item incomes. This additionally prompts a little market potential for new medication use and a financial misfortune for the medication organizations area.

Orphan medication can be characterized as a drug specialist explicitly intended to treat uncommon (orphaned) illnesses. These sicknesses contrast from regular illnesses as their predominance rate is low and consequently appeal to a little tolerant populace. Subsequently, when contrasted with non-orphan drugs, these drugs don't ensure achievable profits from speculation. Nonetheless, different government specialists urge to create and market such drugs. Cost related with the advancement of these drugs is higher when contrasted and non-orphan drugs. The various signs for which orphan drugs are utilized incorporate lymphoma, leukemia, cystic fibrosis, and others.

The rising mindfulness activities are projected to push the interest for orphan drugs. Moreover, expanding instances of metabolic problem and cardiovascular illnesses to support the worldwide orphan drug market towards an amazing development in the impending years. The oncology division of drugs runs over rising number of malignancy patients with different sorts of disease, every year. The number is by all accounts just expanding measurably, to battle the circumstance, there is developing need and interest for the powerful drugs in the medication advancement region. Consequently, the worldwide orphan drug market is projected to see development openings in the approaching years.

The growing geriatric rate of elderly population with constant conditions calls for viable drugs to treat the condition or keep them in charge. Along these lines, the interest for orphan drug builds, inferable from considerable development in the worldwide orphan drug market during the conjecture time frame.

For the purpose of this study, the market has been segmented as follows:

by Disease Type

  • Oncology
  • Gastrointestinal
  • Pulmonary
  • Neurology
  • Hematology
  • Cardio-vascular
  • Metabolic disorders
  • Endocrinology
  • Infectious diseases
  • Others

by Indicator

  • Biologic
  • Non-biologic

by Technology

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail pharmacies
  • Others

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Rest of the World
    • Japan
    • Australia
    • China
    • Brazil
    • South Korea
    • Others
    Section 1 Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights 
     
    Section 2 Assumptions and Research Methodology
     
    Section 3 Executive Summary
     
    Section 4 Market Overview
    4.1. Introduction
            4.1.1 Product Type Definition
    4.2. Overview
    4.3. Market Dynamics 
            4.3.1. Drivers
                             4.3.1.1. Rising prevalence of rare diseases 
                             4.3.1.2. R&D Grants
                             4.3.1.3. Orphan Drugs provide high return on investments
                             4.3.1.4. First-mover advantage
                             4.3.1.5. Focus on awareness programs
                             4.3.1.6. Tax credits and fee waivers
            4.3.2. Restraints
                             4.3.2.1. High cost of treatment
                             4.3.2.2. Dearth of trained medical professionals
                             4.3.2.3. Non-availability of approved drugs worldwide
                             4.3.2.4. Difficulty in recruiting for clinical trials
            4.3.3. Opportunities
                             4.3.3.1. Unmet clinical needs
                             4.3.3.2. Strategic mergers and acquisitions
                             4.3.3.3. Repurposing of drugs
            4.3.4. Trends
    4.5. Global Orphan Drugs Market Analysis and Forecasts, 2015–2025  
    4.6. Market Outlook
    4.7. Porter's Five Forces Analysis
    4.8. Orphan Drug Manufacturing Companies – Acquisitions Timeline
    4.9. Orphan Drugs Market- SWOT Analysis
    4.10. Regulatory Scenario 
    4.11. Comparative Analysis of orphan drug policies
    4.12. Rare Diseases Prevalence
    4.13. Pricing – Orphan Drugs 
    4.14. Orphan Drugs – Price Volume Analysis
    4.15. Major Conferences
    4.16. Major selling Orphan drugs 
    4.17. Orphan Drugs – Drug Exclusivity 
    4.18. Clinical Trial Analysis
     
    Section 5 Global Orphan Drugs Market Analysis and Forecasts, By Disease Type
    5.1. Introduction & Definition
    5.2. Key Findings / Developments
    5.3. Market Value Forecast By Disease Type, 2015–2025 
            5.3.1. Oncology        
            5.3.2. Gastrointestinal
            5.3.3. Pulmonary
            5.3.4. Neurology
            5.3.5. Hematology
            5.3.6. Cardiovascular
            5.3.7. Metabolic Disorders
            5.3.8. Endocrinology
            5.3.9. Infectious Diseases
            5.3.10. Others
    5.4. Market Attractiveness By Disease Type
     
    Section 6 Global Orphan Drugs Market Analysis and Forecasts, By Product Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Product Type, 2015–2025
            6.3.1. Biologic
            6.3.2. Non-biologic
    6.4. Market Attractiveness By Product Type
     
    Section 7 Global Orphan Drugs Market Analysis and Forecasts, By Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Distribution Channel, 2015–2025
            7.3.1. Hospital Pharmacies
            7.3.2. Specialty Pharmacies
            7.3.3. Retail Pharmacies
            7.3.4. Others
    7.4. Market Attractiveness By Distribution Channel
     
    Section 8 Global Orphan Drugs Market Analysis and Forecasts, By Region  
    8.1. Key Findings
    8.2. Market Value Forecast By Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Rest of the World
    8.3. Market Attractiveness by Region
     
    Section 9 North America Orphan Drugs Market Analysis and Forecast
    9.1. Introduction
    9.2. Key Findings
    9.3. Market Value Forecast By Country, 2015-2025
            9.3.1. U.S.
            9.3.2. Canada
    9.4. Market Value Forecast By Disease Type, 2015–2025 
            9.4.1. Oncology
            9.4.2. Gastrointestinal
            9.4.3. Pulmonary
            9.4.4. Neurology
            9.4.5. Hematology
            9.4.6. Cardiovascular
            9.4.7. Metabolic Disorders
            9.4.8. Endocrinology
            9.4.9. Infectious Diseases
            9.4.10. Others
    9.5. Market Value Forecast By Product Type, 2015–2025
            9.5.1. Biologic
            9.5.2. Non-biologic
    9.6. Market Value Forecast By Distribution Channel, 2015–2025
            9.6.1. Hospital Pharmacies
            9.6.2. Specialty Pharmacies
            9.6.3. Retail Pharmacies
            9.6.4. Others
    9.7. Market Attractiveness Analysis
            9.7.1. By Country
            9.7.2. By Disease Type
            9.7.3. By Product Type
            9.7.4. By Distribution Channel
     
    Section 10 Europe Orphan Drugs Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast By Country, 2015-2025
            10.3.1. U.K.
            10.3.2. Germany
            10.3.3. France
            10.3.4. Italy
            10.3.5. Spain 
            10.3.6. Rest of Europe
    10.4. Market Value Forecast By Disease Type, 2015–2025 
            10.4.1. Oncology
            10.4.2. Gastrointestinal
            10.4.3. Pulmonary
            10.4.4. Neurology
            10.4.5. Hematology
            10.4.6. Cardiovascular
            10.4.7. Metabolic Disorders
            10.4.8. Endocrinology
            10.4.9. Infectious Diseases
            10.4.10. Others
    10.5. Market Value Forecast By Product Type, 2015–2025
            10.5.1. Biologic
            10.5.2. Non-biologic
    10.6. Market Value Forecast By Distribution Channel, 2015–2025
            10.6.1. Hospital Pharmacies
            10.6.2. Specialty Pharmacies
            10.6.3. Retail Pharmacies
            10.6.4. Others
    10.7. Market Attractiveness Analysis
            10.7.1. By Country
            10.7.2. By Disease Type
            10.7.3. By Product Type
            10.7.4. By Distribution Channel
     
    Section 11 Rest of the World Orphan Drugs Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast By Country, 2015-2025
            11.3.1. Japan
            11.3.2. Australia
            11.3.3. China
            11.3.4. Brazil
            11.3.5. South Korea 
            11.3.6. Others
    11.4. Market Value Forecast By Disease Type, 2015–2025 
            11.4.1. Oncology
            11.4.2. Gastrointestinal
            11.4.3. Pulmonary
            11.4.4. Neurology
            11.4.5. Hematology
            11.4.6. Cardiovascular
            11.4.7. Metabolic Disorders
            11.4.8. Endocrinology
            11.4.9. Infectious Diseases
            11.4.10. Others
    11.5. Market Value Forecast By Product Type, 2015–2025
            11.5.1. Biologic
            11.5.2. Non-biologic
    11.6. Market Value Forecast By Distribution Channel, 2015–2025
            11.6.1. Hospital Pharmacies
            11.6.2. Specialty Pharmacies
            11.6.3. Retail Pharmacies
            11.6.4. Others
    11.7. Market Attractiveness Analysis
            11.7.1. By Country
            11.7.2. By Disease Type
            11.7.3. By Product Type
            11.7.4. By Distribution Channel
     
    Section 12 Country Snippets
     
    Section 13 Competition Landscape
    13.1. Market Player – Competition Matrix (By Tier and Size of companies)
    13.2. Market Share Analysis By Company, 2016
    13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)  
            13.3.1. Novartis AG 
                      13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.1.2. Business Overview
                      13.3.1.3. Product Portfolio
                      13.3.1.4. Financial Overview
                      13.3.1.5. SWOT Analysis
                      13.3.1.6. Strategic overview
            13.3.2. Bristol-Myers Squibb Company
                      13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.2.2. Business Overview
                      13.3.2.3. Product Portfolio
                      13.3.2.4. Financial Overview
                      13.3.2.5. SWOT Analysis
                      13.3.2.6. Strategic overview 
            13.3.3. Celgene Corporation
                      13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.3.2. Business Overview
                      13.3.3.3. Product Portfolio
                      13.3.3.4. Financial Overview
                      13.3.3.5. SWOT Analysis
                      13.3.3.6. Strategic overview 
            13.3.4. F. Hoffmann-La Roche Ltd. 
                      13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.4.2. Business Overview
                      13.3.4.3. Product Portfolio
                      13.3.4.4. Financial Overview
                      13.3.4.5. SWOT Analysis
                      13.3.4.6. Strategic overview
            13.3.5. Pfizer, Inc. 
                      13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.5.2. Business Overview
                      13.3.5.3. Product Portfolio
                      13.3.5.4. Financial Overview
                      13.3.5.5. SWOT Analysis
                      13.3.5.6. Strategic overview
            13.3.6. Sanofi S.A. 
                      13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.6.2. Business Overview
                      13.3.6.3. Product Portfolio
                      13.3.6.4. Financial Overview
                      13.3.6.5. SWOT Analysis
                      13.3.6.6. Strategic overview
            13.3.7. Alexion Pharmaceuticals, Inc. 
                      13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.7.2. Business Overview
                      13.3.7.3. Product Portfolio
                      13.3.7.4. Financial Overview
                      13.3.7.5. SWOT Analysis
                      13.3.7.6. Strategic overview
            13.3.8. Eli Lilly and Company
                      13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.8.2. Business Overview
                      13.3.8.3. Product Portfolio
                      13.3.8.4. Financial Overview
                      13.3.8.5. SWOT Analysis
                      13.3.8.6. Strategic overview
            13.3.9. Novo Nordisk A/S 
                      13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.9.2. Business Overview
                      13.3.9.3. Product Portfolio
                      13.3.9.4. Financial Overview
                      13.3.9.5. SWOT Analysis
                      13.3.9.6. Strategic overview
            13.3.10. AstraZeneca plc 
                      13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.10.2. Business Overview
                      13.3.10.3. Product Portfolio
                      13.3.10.4. Financial Overview
                      13.3.10.5. SWOT Analysis
                      13.3.10.6. Strategic overview
            13.3.11. Eisai Co., Ltd.
                      13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.11.2. Business Overview
                      13.3.11.3. Product Portfolio
                      13.3.11.4. Financial Overview
                      13.3.11.5. SWOT Analysis
                      13.3.11.6. Strategic overview
            13.3.12. Daiichi Sankyo Company Limited 
                      13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.12.2. Business Overview
                      13.3.12.3. Product Portfolio
                      13.3.12.4. Financial Overview
                      13.3.12.5. SWOT Analysis
                      13.3.12.6. Strategic overview
            13.3.13. Bayer AG 
                      13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.13.2. Business Overview
                      13.3.13.3. Product Portfolio
                      13.3.13.4. Financial Overview
                      13.3.13.5. SWOT Analysis
                      13.3.13.6. Strategic overview
            13.3.14. GlaxoSmithKline plc 
                      13.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.14.2. Business Overview
                      13.3.14.3. Product Portfolio
                      13.3.14.4. Financial Overview
                      13.3.14.5. SWOT Analysis
                      13.3.14.6. Strategic overview
            13.3.15. Merck & Co., Inc. 
                      13.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.15.2. Business Overview
                      13.3.15.3. Product Portfolio
                      13.3.15.4. Financial Overview
                      13.3.15.5. SWOT Analysis
                      13.3.15.6. Strategic overview
            13.3.16. Johnson & Johnson 
                      13.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.16.2. Business Overview
                      13.3.16.3. Product Portfolio
                      13.3.16.4. Financial Overview
                      13.3.16.5. SWOT Analysis
                      13.3.16.6. Strategic overview
            13.3.17. Biogen, Inc. 
                      13.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.17.2. Business Overview
                      13.3.17.3. Product Portfolio
                      13.3.17.4. Financial Overview
                      13.3.17.5. SWOT Analysis
                      13.3.17.6. Strategic overview
            13.3.18. Shire plc
                      13.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.18.2. Business Overview
                      13.3.18.3. Product Portfolio
                      13.3.18.4. Financial Overview
                      13.3.18.5. SWOT Analysis
                      13.3.18.6. Strategic overview
            13.3.19. Amgen, Inc.
                      13.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.19.2. Business Overview
                      13.3.19.3. Product Portfolio
                      13.3.19.4. Financial Overview
                      13.3.19.5. SWOT Analysis
                      13.3.19.6. Strategic overview

    List of Tables

    Table 01: Comparative Analysis of orphan drug policies
    Table 02: Top selling orphan drugs of 2016
    Table 03: Orphan Drugs- Drug Exclusivity Details (of Few Orphan Drugs)
    Table 04: Pipeline Analysis
    Table 05: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
    Table 06: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 07: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 08: Global Orphan Drugs Market Size (US$ Bn) Forecast, by Region, 2015–2025
    Table 09: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 10: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 11: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
    Table 12: North America Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 13: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 14: Europe Orphan Drug Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 15: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
    Table 16: Europe Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 17: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 18: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 19: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Disease Type, 2015–2025
    Table 20: Rest of the World Orphan Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Figure 01: Global Orphan Drugs Market Size (US$ Mn) and Y-o-Y Growth (%), and Forecast, 2017–2025
    Figure 02: Market Value Share By Disease Type (2017)
    Figure 03: Market Value Share By Product Type (2017)
    Figure 04: Market Value Share By Distribution Channel (2017)
    Figure 05: Market Value Share By Region (2017)
    Figure 06: Porter’s Five Force Analysis
    Figure 07: Orphan Drugs Market- SWOT Analysis
    Figure 08: Regulatory Approval Process- The U.S.
    Figure 09: Regulatory Approval Process- Europe
    Figure 10: Regulatory Approval Process- Japan
    Figure 11: Prevalence of Orphan (rare) diseases
    Figure 12: Factors contributing to the orphan drugs pricing decision
    Figure 13: Pricing of certain orphan drugs (US$ per patient per year)
    Figure 14: Factors for high prices of orphan drugs
    Figure 15: Orphan Drugs- Price Volume Analysis
    Figure 16: Conferences held on Orphan Diseases
    Figure 17: Global Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 18: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Oncology, 2015–2025
    Figure 19: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Gastrointestinal, 2015–2025
    Figure 20: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Pulmonary, 2015–2025
    Figure 21: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Neurology, 2015–2025
    Figure 22: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Hematology, 2015–2025
    Figure 23: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Cardiovascular,
    Figure 24: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Metabolic Disorders, 2015–2025
    Figure 25: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Endocrinology,
    Figure 26: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Infectious Diseases, 2015–2025
    Figure 27: Global Orphan Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
    Figure 28: Global Orphan Drugs Market Attractiveness, by Disease Type, 2017-2025
    Figure 29: Global Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 30: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Biologic, 2015–2025
    Figure 31: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%), by Non-biologic, 2015–2025
    Figure 32: Global Orphan Drugs Market Attractiveness, by Product Type 2017-2025
    Figure 33: Global Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 34: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2015–2025
    Figure 35: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Specialty Pharmacies, 2015–2025
    Figure 36: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Retail Pharmacies,
    Figure 37: Global Orphan Drugs Market Revenue (US$ Bn), and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
    Figure 38: Global Orphan Drugs Market Attractiveness, by Distribution Channel, 2017-2025
    Figure 39: Global Orphan Drugs Market Revenue (US$ Bn) Forecast, 2015–2025
    Figure 40: Global Orphan Drugs Market Value Share Analysis, by Region, 2016 and 2025
    Figure 41: Global Orphan Drugs Market Attractiveness, by Region, 2017-2025
    Figure 42: North America Orphan Drugs Market Size (US$ Bn) and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 43: North America Orphan Drugs Market Attractiveness Analysis, by Country, 2017–2025
    Figure 44: North America Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
    Figure 45: North America Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 46: North America Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 47: North America Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 48: North America Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017–2025
    Figure 49: North America Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 50: North America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017–2025
    Figure 51: Europe Orphan Drug Market Size (US$ Bn) Forecast, 2015–2025
    Figure 52: Europe Market Attractiveness Analysis, by Country, 2017–2025
    Figure 53: Europe Orphan Drug Market Value Share Analysis, by Country, 2016 and 2025
    Figure 54: Europe Orphan Drug Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 55: Europe Orphan Drug Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 56: Europe Orphan Drug Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 57: Europe Orphan Drug Market Attractiveness Analysis, by Product type, 2017–2025
    Figure 58: Europe Orphan Drug Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 59: Europe Orphan Drug Market Attractiveness Analysis, by Disease Type, 2017–2025
    Figure 60: Rest of the World Orphan Drugs Market Size (US$ Bn)  and Y-o-Y Growth (%) Forecast, 2015–2025
    Figure 61: Rest of the World Market Attractiveness Analysis, by Country, 2017–2025
    Figure 62: Rest of the World Orphan Drugs Market Value Share Analysis, by Country, 2016 and 2025
    Figure 63: Rest of the World Orphan Drugs Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 64: Rest of the World Orphan Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 65: Rest of the World Orphan Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 66: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Product Type, 2017–2025
    Figure 67: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 68: Rest of the World Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2017–2025
    Figure 69: Global Orphan Drugs Market Share Analysis, by Company (2016)
    Figure 70: Novartis AG, Breakdown of Net Sales, by Region, 2016
    Figure 71: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 72: Bristol-Myers Squibb Company, Breakdown of Net Sales, by Region, 2016
    Figure 73: Bristol-Myers Squibb Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 74: Celgene Corporation, Breakdown of Net Sales, by Region, 2016
    Figure 75: Celgene Corporation, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 76: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales (Pharmaceutical Division), by Region, 2016
    Figure 77: F. Hoffmann-La Roche Ltd., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 78: Pfizer, Inc., Breakdown of Net Sales, by Region, 2016
    Figure 79: Pfizer, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 80: Sanofi S.A., Breakdown of Net Sales, by Region, 2016
    Figure 81: Sanofi S.A., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 82: Alexion pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2016
    Figure 83: Alexion pharmaceuticals, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 84: Eli Lilly and Company, Breakdown of Net Sales, by Region, 2016
    Figure 85: Eli Lilly and Company, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 86: Novo Nordisk A/S, Breakdown of Net Sales, by Region, 2016
    Figure 87: Novo Nordisk A/S, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 88: AstraZeneca plc, Breakdown of Net Sales, by Region, 2016
    Figure 89: AstraZeneca plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 90: Eisai Co., Ltd., Breakdown of Net Sales, by Region, 2016
    Figure 91: Eisai Co., Ltd., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 92: Daiichi Sankyo Company Limited, Breakdown of Net Sales, by Region, 2016
    Figure 93: Daiichi Sankyo Company Limited, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 94: Bayer AG, Breakdown of Net Sales, by Region
    Figure 95: Bayer AG, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 96: GlaxoSmithKline plc, Breakdown of Net Sales, by Region, 2016
    Figure 97: GlaxoSmithKline plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 98: Merck & Co., Inc., Breakdown of Net Sales, by Region, 2016
    Figure 99: Merck & Co., Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 100: Johnson & Johnson, Breakdown of Net Sales, by Region, 2016
    Figure 101: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 102: Biogen, Inc., Breakdown of Net Sales, by Region, 2016
    Figure 103: Biogen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 104: Shire plc, Breakdown of Net Sales, by Region, 2016
    Figure 105: Shire plc, Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 106: Amgen, Inc., Breakdown of Net Sales, by Region, 2016
    Figure 107: Amgen, Inc., Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016

Copyright © Transparency Market Research, Inc. All Rights reserved